Gilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug

Published Apr 30 2021 at 10:01 AM GMT
Key
Points
  • With Veklury, Gilead delivered solid revenue growth in Q1.
  • Without the COVID drug, it was an entirely different story.




Stats

  • Published Apr 30, 2021 10:01 AM GMT